Jonathan Storey Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company developing gene and cell therapies using its proprietary platforms. They aim to restore retinal function in various ocular diseases. Since I last covered OCGN, the company has made promising strides targeting conditions such as retinitis pigmentosa [RP], geographic atrophy related to dry age-related macular degeneration [dAMD], Stargardt disease, and wet AMD. It also has an intriguing candidate addressing defects in knee ...